The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | Monitoring, diagnosing & managing cardiotoxicity in AL amyloidosis
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses the monitoring, diagnosis, and management of cardiotoxicity in light chain (AL) amyloidosis. Close monitoring of cardiac biomarkers, such as NT-proBNP and high-sensitivity troponin, is essential. Adjusting treatment based on these biomarkers and patient functional status may be necessary. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
